Shares of vTv Therapeutics Inc (NASDAQ:VTVT) have earned a consensus recommendation of “Buy” from the eight research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $18.17.
Several equities analysts have issued reports on the company. Roth Capital assumed coverage on vTv Therapeutics in a research note on Thursday, March 8th. They issued a “buy” rating and a $17.00 price target on the stock. Zacks Investment Research lowered vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Northland Securities assumed coverage on vTv Therapeutics in a research note on Thursday, February 8th. They issued an “outperform” rating and a $28.00 price target on the stock. Finally, Canaccord Genuity set a $15.00 price target on vTv Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 21st.
In other news, major shareholder Ronald O. Perelman bought 50,000 shares of the stock in a transaction dated Tuesday, December 26th. The shares were bought at an average cost of $4.03 per share, with a total value of $201,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.80% of the stock is owned by corporate insiders.
vTv Therapeutics (NASDAQ VTVT) opened at $6.85 on Tuesday. vTv Therapeutics has a 12 month low of $3.57 and a 12 month high of $8.40. The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of -0.10. The stock has a market capitalization of $210.66 and a P/E ratio of -6.46.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.